Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1058) 1058
Publication (101) 101
Book Chapter (19) 19
Book Review (8) 8
Conference Proceeding (5) 5
Book / eBook (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (683) 683
transplantation (618) 618
index medicus (615) 615
hematology (601) 601
male (468) 468
female (455) 455
bone-marrow-transplantation (409) 409
stem cells (390) 390
immunology (375) 375
adult (359) 359
hematopoietic stem cells (349) 349
haploidentical (323) 323
adolescent (300) 300
middle aged (291) 291
oncology (286) 286
versus-host-disease (274) 274
hematopoietic stem cell transplantation - methods (250) 250
child (249) 249
hematopoietic stem cell transplantation (246) 246
leukemia (228) 228
transplantation, homologous (204) 204
young adult (201) 201
treatment outcome (197) 197
child, preschool (189) 189
children (170) 170
stem-cell transplantation (170) 170
t cells (170) 170
haploidentical transplantation (165) 165
transplantation conditioning - methods (158) 158
graft vs host disease - prevention & control (157) 157
cyclophosphamide (155) 155
hematologic malignancies (154) 154
stem cell transplantation (150) 150
haplotypes (146) 146
bone marrow (145) 145
acute myeloid-leukemia (141) 141
hematology, oncology and palliative medicine (139) 139
hematopoietic stem cell transplantation - adverse effects (135) 135
unrelated donors (134) 134
aged (124) 124
analysis (122) 122
tissue donors (121) 121
care and treatment (118) 118
retrospective studies (118) 118
transplantation conditioning (117) 117
mortality (113) 113
posttransplantation cyclophosphamide (113) 113
health aspects (111) 111
pediatrics (110) 110
relapse (110) 110
hematologic neoplasms - therapy (108) 108
histocompatibility testing (108) 108
acute-leukemia (106) 106
graft vs host disease - etiology (106) 106
haploidentical stem cell transplantation (104) 104
outcomes (103) 103
survival analysis (103) 103
disease-free survival (98) 98
cancer (97) 97
immune reconstitution (94) 94
infant (94) 94
blood (93) 93
donors (93) 93
bone marrow transplantation (92) 92
hla antigens - immunology (92) 92
risk factors (91) 91
graft survival (90) 90
graft vs host disease - immunology (90) 90
research (87) 87
recurrence (86) 86
immunotherapy (85) 85
transplants & implants (81) 81
antithymocyte globulin (76) 76
histocompatibility (75) 75
article (74) 74
surgical procedures, operative (74) 74
survival rate (74) 74
graft-versus-host reaction (73) 73
graft-versus-host disease (72) 72
high-risk (72) 72
survival (70) 70
t-lymphocytes - immunology (70) 70
cyclophosphamide - therapeutic use (69) 69
leukemia, myeloid, acute - therapy (68) 68
patient outcomes (68) 68
follow-up studies (67) 67
acute disease (64) 64
acute lymphoblastic-leukemia (64) 64
bone-marrow (64) 64
killer cells, natural - immunology (64) 64
histocompatibility antigens (63) 63
transplantation, haploidentical - methods (63) 63
cord blood transplantation (62) 62
graft vs host disease - mortality (62) 62
hla histocompatibility antigens (62) 62
immunosuppressive agents - therapeutic use (62) 62
leukemia - therapy (62) 62
peripheral-blood (62) 62
disease (60) 60
engraftment (60) 60
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1044) 1044
French (13) 13
German (11) 11
Japanese (3) 3
Polish (3) 3
Hungarian (2) 2
Spanish (2) 2
Korean (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text T Cell–Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia
by How, Joan and Slade, Michael and Vu, Khoan and DiPersio, John F and Westervelt, Peter and Uy, Geoffrey L and Abboud, Camille N and Vij, Ravi and Schroeder, Mark A and Fehniger, Todd A and Romee, Rizwan
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2017, Volume 23, Issue 4, pp. 648 - 653
Highlights • Acute myeloid leukemia patients not able to achieve remission or relapsed after previous remission continue to have extremely poor prognosis •... 
Hematology, Oncology and Palliative Medicine | Active disease | Acute myeloid leukemia | Haploidentical transplantation | SURVIVAL | BONE-MARROW-TRANSPLANTATION | LYMPHOCYTE INFUSIONS | IMMUNOLOGY | CHRONIC GRAFT | CHEMOTHERAPY | TRANSPLANTATION | HLA-IDENTICAL SIBLINGS | SUPERIOR | HOST-DISEASE | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | REMISSION | Age Factors | Hematopoietic Stem Cell Transplantation - standards | Humans | Middle Aged | Male | Hematopoietic Stem Cell Transplantation - mortality | Transplantation, Haploidentical - mortality | Cyclophosphamide - therapeutic use | Graft vs Host Disease | Young Adult | Transplantation, Haploidentical - methods | Adult | Female | Retrospective Studies | Leukemia, Myeloid, Acute - therapy | Risk Factors | Treatment Outcome | Leukemia, Myeloid, Acute - mortality | T-Lymphocytes - cytology | Survival Analysis | Aged | Hematopoietic Stem Cell Transplantation - methods | Transplantation, Haploidentical - standards | Histocompatibility | Tissue Donors - supply & distribution | Cyclophosphamide | Transplantation | T cells | Hematopoietic stem cells | Analysis | Mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text T‐cell–depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT)
by Sestili, Simona and Labopin, Myriam and Ruggeri, Annalisa and Velardi, Andrea and Ciceri, Fabio and Maertens, Johan and Kanz, Lothar and Aversa, Franco and Lewalle, Philippe and Bunjes, Donald and Mohty, Mohamad and Nagler, Arnon
Cancer, ISSN 0008-543X, 05/2018, Volume 124, Issue 10, pp. 2142 - 2150
Outcomes of T‐cell–depleted, haploidentical transplantation for acute leukemia in Europe have improved over time. In this registry‐based study, 208 patients... 
T‐cell depletion | haploidentical transplantation | time | outcomes | acute leukemia | T-cell depletion | INTENSITY | PHASE-II | DONORS | CONDITIONING REGIMEN | CHEMOTHERAPY | CHILDREN | IMPACT | ONCOLOGY | RISK ACUTE-LEUKEMIA | HAPLOTYPE | REMISSION | Treatment outcome | Care and treatment | Usage | Analysis | Stem cells | Acute leukemia | Adults | Transplantation | Research | T cells | Health aspects | Graft-versus-host reaction | Myeloid leukemia | Leukemia | Stem cell transplantation | Lymphocytes T | Multivariate analysis | Patients | Survival | Incidence | White blood cells | Depletion | Remission | Histocompatibility antigen HLA | Acute myeloid leukemia | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard‐risk acute lymphoblastic leukaemia in first complete remission
by Han, Li‐Jie and Wang, Yu and Fan, Zhi‐Ping and Huang, Fen and Zhou, Jian and Fu, Yue‐Wen and Qu, Hong and Xuan, Li and Xu, Na and Ye, Jie‐Yu and Bian, Zhi‐Lei and Song, Yong‐Ping and Huang, Xiao‐Jun and Liu, Qi‐Fa
British Journal of Haematology, ISSN 0007-1048, 10/2017, Volume 179, Issue 1, pp. 120 - 130
We retrospectively investigated outcomes of haploidentical donor ( HID ) transplant for adults with standard‐risk acute lymphoblastic leukaemia ( ALL ) in... 
standard‐risk | first complete remission | haematopoietic stem cell transplantation | haploidentical donor | acute lymphoblastic leukaemia | standard-risk | POSTREMISSION THERAPY | CONVENTIONAL CONSOLIDATION/MAINTENANCE CHEMOTHERAPY | IMPROVES SURVIVAL | VERSUS-HOST-DISEASE | REPLETE | RELAPSE | IMPACT | SUPERIOR | OUTCOMES | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Haplotypes | Recurrence | Humans | Middle Aged | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Transplantation, Homologous | Incidence | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Unrelated Donors | Retrospective Studies | Graft vs Host Disease - diagnosis | Graft vs Host Disease - etiology | Siblings | Graft Survival | Treatment Outcome | Combined Modality Therapy | Remission Induction | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Adolescent | Survival Analysis | Graft vs Host Disease - prevention & control | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning | Adults | Transplantation | Comparative analysis | Hematopoietic stem cells | Stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor–Mobilized Donor Lymphocyte Infusions
by Jaiswal, Sarita Rani and Zaman, Shamsuz and Chakrabarti, Aditi and Sen, Subrata and Mukherjee, Shashwata and Bhargava, Sneh and Ray, Kunal and O'Donnell, Paul V and Chakrabarti, Suparno
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 10, pp. 1867 - 1873
Highlights • PTCy provides a suitable platform for exploring adoptive immunotherapy after both myeloablative and nonmyeloablative conditioning. • Early and... 
Hematology, Oncology and Palliative Medicine | AML | Refractory | DLI | Haploidentical | Post-transplantation cyclophosphamide | SURVIVAL | HEMATOPOIETIC SCT | BONE-MARROW-TRANSPLANTATION | IMMUNOLOGY | VERSUS-HOST-DISEASE | TRANSPLANTATION | RELAPSE | WORKING GROUP | STAGE ACUTE-LEUKEMIA | MISSING SELF | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Myeloablative Agonists - therapeutic use | Salvage Therapy - adverse effects | Humans | Middle Aged | Child, Preschool | Male | Transplantation, Haploidentical - mortality | Young Adult | Transplantation, Haploidentical - methods | Killer Cells, Natural - immunology | Adult | Female | Lymphocyte Transfusion | Transplantation Conditioning - methods | Child | Salvage Therapy - mortality | Killer Cells, Natural - transplantation | Immunotherapy, Adoptive - methods | Treatment Outcome | Granulocyte Colony-Stimulating Factor - therapeutic use | Disease Progression | Immunotherapy, Adoptive - trends | Disease-Free Survival | Adolescent | Transplantation, Haploidentical - adverse effects | Aged | Receptors, KIR - immunology | Salvage Therapy - methods | Killer cells | Cyclophosphamide | Macrophage colony stimulating factor | Granulocyte colony-stimulating factor | Immunotherapy | Stem cells | Bone marrow | Transplantation | Hematopoietic stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey
by Niederwieser, D and Baldomero, H and Szer, J and Gratwohl, M and Aljurf, M and Atsuta, Y and Bouzas, L.F and Confer, D and Greinix, H and Horowitz, M and Iida, M and Lipton, J and Mohty, M and Novitzky, N and Nunez, J and Passweg, J and Pasquini, M.C and Kodera, Y and Apperley, J and Seber, A and Gratwohl, A and Worldwide Network Blood Marrow Tra and for the Worldwide Network of Blood and Marrow Transplantation (WBMT)
Bone Marrow Transplantation, ISSN 0268-3369, 06/2016, Volume 51, Issue 6, pp. 778 - 785
Data on 68 146 hematopoietic stem cell transplants (HSCTs) (53% autologous and 47% allogeneic) gathered by 1566 teams from 77 countries and reported through... 
EUROPE | PERSPECTIVE | ONCOLOGY | SCT | DONORS | IMMUNOLOGY | HEMATOLOGY | TRENDS | ORGAN-TRANSPLANTATION | TRANSPLANTATION | Hematopoietic Stem Cell Transplantation - statistics & numerical data | Hematopoietic Stem Cell Transplantation - utilization | Humans | Bone Marrow Transplantation | Global Health - statistics & numerical data | Surveys and Questionnaires | Tissue Donors | Transplantation, Haploidentical | Peripheral Blood Stem Cell Transplantation | Transplantation, Homologous | Cord Blood Stem Cell Transplantation | Surveys | Health care industry | Forecasts and trends | Transplantation | Medical statistics | Hematopoietic stem cells | Usage | Analysis | Stem cells | Research | Data entry | emerging technologies | Non Governmental Organization | SWOT analysis | Worldwide Network for Blood and Marrow Transplantation WBMT | global | transplant rates | hematopoietic stem cell transplantation (HSCT) | haploidentical transplants | cord blood transplants | trends | WHO
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text T cell Replete HLA- Haploidentical Donor Transplantation (HIDT) with Post-Transplant Cyclophosphamide (PTCY) is an Effective Salvage for Patients Relapsing after an HLA- Matched Related (MRDT) or a Matched Unrelated Donor Transplantation (MUDT)
by Gorgeis, Jessica, D.Ph and Zhang, Xu, Ph.D and Connor, Katelin, R.N and Brown, Stacey and Solomon, Scott R., M.D and Morris, Lawrence E., M.D and Holland, H. Kent, M.D and Bashey, Asad, M.D., Ph.D and Solh, Melhem, M.D
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 10, pp. 1861 - 1866
Highlights • Relapse after a matched related (MRD) or unrelated (MUD) transplantation carries a very bad prognosis. • Second allogeneic transplantation using... 
Hematology, Oncology and Palliative Medicine | Relapse | Second | Haploidentical | Transplant | DISEASE RISK INDEX | SURVIVAL | GRAFTS | BONE-MARROW-TRANSPLANTATION | ALLOGENEIC TRANSPLANT | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | SIBLING DONORS | TRANSPLANTATION | OUTCOMES | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | BLOOD | Hematologic Neoplasms - therapy | Recurrence | Salvage Therapy - adverse effects | Cyclophosphamide - administration & dosage | T-Lymphocytes | Hematologic Neoplasms - mortality | Humans | Middle Aged | HLA Antigens - immunology | Graft Survival | Male | Lymphocyte Depletion | Graft vs Host Disease | Young Adult | Haploidy | Transplantation, Haploidentical - methods | Adult | Female | Retrospective Studies | Hematologic Neoplasms - complications | Tissue Donors | Histocompatibility | Salvage Therapy - methods | Salvage Therapy - mortality | T cells | Cyclophosphamide | Analysis | Leukemia | Mortality | Stem cells | Bone marrow | Transplantation | Hematopoietic stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: Nine years of experience at a single center
by Wang, Yu and Liu, Dai-Hong and Liu, Kai-Yan and Xu, Lan-Ping and Zhang, Xiao-Hui and Han, Wei and Chen, Huan and Chen, Yu-Hong and Wang, Feng-Rong and Wang, Jing-Zhi and Sun, Yu-Qian and Huang, Xiao-Jun
Cancer, ISSN 0008-543X, 03/2013, Volume 119, Issue 5, pp. 978 - 985
BACKGROUND: Many patients who require allogeneic hematopoietic stem cell transplantation (allo-HSCT) lack a human leukocyte antigen (HLA)-matched donor.... 
hematopoietic stem cell transplantation | mismatched | haploidentical | human leukocyte antigen | allogeneic | HLA-MISMATCHED/HAPLOIDENTICAL BLOOD | MATERNAL ANTIGENS | BONE-MARROW-TRANSPLANTATION | TOLERANCE | DONOR LYMPHOCYTE INFUSION | RELAPSE | ONCOLOGY | HIGH-RISK | SIBLING DONOR | MYELOID-LEUKEMIA | HEMATOLOGIC MALIGNANCIES | Haplotypes | Follow-Up Studies | Humans | Middle Aged | Leukemia - therapy | Male | Treatment Outcome | Lymphocyte Depletion | Graft vs Host Disease - immunology | Transplantation Chimera | Transplantation, Homologous | Young Adult | Adolescent | Adult | Female | HLA Antigens | Hematopoietic Stem Cell Transplantation - methods | Histocompatibility | Blood Transfusion - methods | Usage | Care and treatment | Patient outcomes | Leukemia | Cellular therapy | Stem cells | Transplantation | Methods | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Hematopoietic stem cell transplantation in Europe 2014 : more than 40 000 transplants annually
by Passweg, J. R and Baldomero, H and Bader, P and Bonini, C and Cesaro, S and ger, P and Duarte, R. F and Dufour, C and Kuball, J and Farge-Bancel, D and Gennery, A and Kröger, N and Lanza, F and Nagler, A and Sureda, A and Mohty, M and for the European Society for Blood and Marrow Transplantation (EBMT)
Bone Marrow Transplantation, ISSN 0268-3369, 02/2016, Volume 51, Issue 6, pp. 786–792 - 792
A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by... 
Amyloidosis - therapy | Hematopoietic Stem Cell Transplantation - trends | Europe | Hematopoietic Stem Cell Transplantation - statistics & numerical data | Humans | Patient Care Team - trends | Cord Blood Stem Cell Transplantation - statistics & numerical data | Transplantation, Autologous | Anemia, Aplastic - therapy | Transplantation, Homologous | Patient Care Team - statistics & numerical data | Neoplasms - therapy | Hematopoietic Stem Cell Transplantation - utilization | Tissue Donors - statistics & numerical data | Surveys and Questionnaires | Hematopoietic Stem Cell Transplantation - methods | Transplantation, Haploidentical | Fetal blood | Usage | Transplantation | Research | Hematopoietic stem cells | Stem cells | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T‐cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
by Canaani, Jonathan and Labopin, Myriam and Huang, Xiao J and Ciceri, Fabio and Van Lint, Maria T and Bruno, Benedetto and Santarone, Stella and Diez‐Martin, José L and Blaise, Didier and Chiusolo, Patrizia and Wu, Depei and Mohty, Mohamad and Nagler, Arnon
British Journal of Haematology, ISSN 0007-1048, 11/2018, Volume 183, Issue 3, pp. 411 - 420
Assessment of minimal residual disease ( MRD ) is being routinely used to assess response in patients with acute myeloid leukaemia ( AML ). While it is well... 
minimal residual disease | cytomegalovirus | acute myeloid leukaemia | relapse | haploidentical stem cell transplantation | SURVIVAL | PROGNOSTIC IMPACT | ADULTS | UNRELATED DONOR TRANSPLANTATION | POSTTRANSPLANT CYCLOPHOSPHAMIDE | REDUCED-INTENSITY | ACUTE LYMPHOBLASTIC-LEUKEMIA | FLOW-CYTOMETRY | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | Medical research | Analysis | Stem cells | Medicine, Experimental | Bone marrow | Transplantation | T cells | Transplants & implants | Leukemia | Minimal residual disease | Stem cell transplantation | Lymphocytes T | Multivariate analysis | Patients | Survival | Blood | Donors | Remission
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Single Antigen–Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors
by Jorge, Ana Sofia and Suárez-Lledó, María and Pereira, Arturo and Gutierrez, Gonzalo and Fernández-Avilés, Francesc and Rosiñol, Laura and Llobet, Noemí and Solano, Teresa and Urbano-Ispízua, Álvaro and Rovira, Montserrat and Martínez, Carmen
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 06/2018, Volume 24, Issue 6, pp. 1196 - 1202
The optimal prophylaxis regimen for graft-versus-host disease (GVHD) in the setting of mismatched unrelated donor (MMUD) allogeneic hematopoietic stem cell... 
Graft-versus-host disease | HLA-mismatched transplantation | Unrelated donor | Post-transplantation cyclophosphamide | BONE-MARROW-TRANSPLANTATION | ANTITHYMOCYTE GLOBULIN | IMMUNOLOGY | VERSUS-HOST-DISEASE | CONDITIONING REGIMEN | TRANSPLANTATION | ACUTE-LEUKEMIA | HIGH-RISK | HAPLOIDENTICAL TRANSPLANTATION | IDENTICAL SIBLINGS | CLASS-I | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | Recurrence | Cyclophosphamide - administration & dosage | Hematopoietic Stem Cell Transplantation - standards | Histocompatibility Testing | Humans | Middle Aged | Male | Transplantation, Homologous | Young Adult | Tacrolimus - therapeutic use | Survival Analysis | Adult | Female | Graft vs Host Disease - prevention & control | Unrelated Donors | Aged | Retrospective Studies | Hematopoietic Stem Cell Transplantation - methods | Drug Therapy, Combination | Histocompatibility | Antigens | Cyclophosphamide | Usage | Analysis | Leukemia | Stem cells | Dosage and administration | Transplantation | Hematopoietic stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Epstein-Barr Virus–Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes
by Xu, Lan-Ping and Zhang, Chun-Li and Mo, Xiao-Dong and Zhang, Xiao-Hui and Chen, Huan and Han, Wei and Chen, Yu-Hong and Wang, Yu and Yan, Chen-Hua and Wang, Jing-Zhi and Wang, Feng-Rong and Zhao, Ting and Liu, Yan-Rong and Liu, Kai-Yan and Huang, Xiao-Jun
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 12, pp. 2185 - 2191
Abstract We examined the incidence, risk factors, treatments, and clinical outcomes of post-transplantation lymphoproliferative disorder (PTLD) after... 
Hematology, Oncology and Palliative Medicine | Epstein-Barr virus–related post-transplantation lymphoproliferative disorder | Immune reconstitution | Rituximab | Haploidentical | Hematopoietic stem cell transplantation | Epstein-Barr virus-related post-transplantation lymphoproliferative disorder | MANAGEMENT | BONE-MARROW-TRANSPLANTATION | IMMUNOLOGY | RECIPIENTS | TRANSPLANTATION | ACUTE-LEUKEMIA | EBV REACTIVATION | HEMATOLOGICAL MALIGNANCIES | DISEASE | HEMATOLOGY | T-LYMPHOCYTES | BLOOD | Haplotypes | CD8-Positive T-Lymphocytes - pathology | Hematologic Neoplasms - mortality | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | DNA, Viral - isolation & purification | Child, Preschool | Male | Hematologic Neoplasms - pathology | Transplantation, Homologous | Rituximab - therapeutic use | Adult | Female | Herpesvirus 4, Human - pathogenicity | Retrospective Studies | Child | Cytomegalovirus - genetics | Histocompatibility Testing | Epstein-Barr Virus Infections - immunology | Risk Factors | Herpesvirus 4, Human - immunology | Treatment Outcome | Epstein-Barr Virus Infections - drug therapy | Epstein-Barr Virus Infections - pathology | Immunoglobulin M - blood | CD8-Positive T-Lymphocytes - virology | Adolescent | Survival Analysis | Epstein-Barr Virus Infections - mortality | Hematologic Neoplasms - drug therapy | Hematologic Neoplasms - immunology | Hematopoietic Stem Cell Transplantation - methods | CD8-Positive T-Lymphocytes - immunology | DNA, Viral - genetics | Histocompatibility antigens | HLA histocompatibility antigens | Stem cells | Transplantation | Epstein-Barr virus | T cells | Hematopoietic stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors
by Solomon, Scott R and Sizemore, Connie A and Sanacore, Melissa and Zhang, Xu and Brown, Stacey and Holland, H. Kent and Morris, Lawrence E and Bashey, Asad
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 7, pp. 1299 - 1307
Abstract We enrolled 30 patients on a prospective phase II trial utilizing a total body irradiation (TBI)–based myeloablative preparative regimen (fludarabine... 
Hematology, Oncology and Palliative Medicine | Stem cell transplantation | Myeloablative | Total body irradiation | Haploidentical | Peripheral blood stem cells | HEMORRHAGIC CYSTITIS | BONE-MARROW-TRANSPLANTATION | IMMUNOLOGY | 2-STEP APPROACH | VERSUS-HOST-DISEASE | CONDITIONING REGIMEN | TRANSPLANTATION | REDUCED-INTENSITY | EUROPEAN-GROUP | HIGH-RISK | LEUKEMIA WORKING PARTY | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | Haplotypes | Hematologic Neoplasms - therapy | Myeloablative Agonists - therapeutic use | Recurrence | Whole-Body Irradiation | Prospective Studies | Hematologic Neoplasms - mortality | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Risk | Hematologic Neoplasms - pathology | Graft vs Host Disease - immunology | Cyclophosphamide - therapeutic use | Graft vs Host Disease - mortality | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Unrelated Donors | Graft vs Host Disease - etiology | Acute Disease | Histocompatibility Testing | Transplantation, Isogeneic | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Survival Analysis | Graft vs Host Disease - prevention & control | Hematologic Neoplasms - immunology | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning | Chronic Disease | Leukemia | Immunotherapy | Mortality | Stem cells | Transplantation | Lymphomas | Mycophenolate mofetil | T cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders
by Klein, Orly R and Chen, Allen R and Gamper, Christopher and Loeb, David and Zambidis, Elias and Llosa, Nicolas and Huo, Jeffrey and Dezern, Amy E and Steppan, Diana and Robey, Nancy and Jo Holuba, Mary and Cooke, Kenneth R and Symons, Heather J
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 5, pp. 895 - 901
Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) is curative for many nonmalignant pediatric disorders, including hemoglobinopathies, bone... 
Hematology, Oncology and Palliative Medicine | Bone marrow failure syndromes | Reduced-intensity conditioning | Cyclophosphamide | HLA-haploidentical | Immunodeficiency | ALEMTUZUMAB | SINGLE-CENTER EXPERIENCE | BONE-MARROW-TRANSPLANTATION | CHRONIC GRANULOMATOUS-DISEASE | IMMUNOLOGY | VERSUS-HOST-DISEASE | FLUDARABINE | HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS | TRANSPLANTATION | PROPHYLAXIS | CORD BLOOD TRANSPLANTATION | HEMATOLOGY | PRIMARY IMMUNODEFICIENCY | Cyclophosphamide - administration & dosage | Humans | Child, Preschool | Hematopoietic Stem Cell Transplantation | Infant | Male | Adolescent | Adult | Female | Graft vs Host Disease - prevention & control | Unrelated Donors | Transplantation Conditioning | Mycophenolic Acid - administration & dosage | Child | Tacrolimus - administration & dosage | Antimitotic agents | Mortality | Stem cells | Bone marrow | Transplantation | Children | Antineoplastic agents | Health aspects | Hematopoietic stem cells | Immunosuppressive agents | cyclophosphamide | immunodeficiency | bone marrow failure syndromes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights